Mereo Biopharma Group Plc ADR (NASDAQ:MREO) traded at $2.89 at close of the session on current trade day and made an upward move of 0.70% on its previous day’s price.
Mereo Biopharma Group Plc ADR has a market cap of $447.17 million and is expected to release its quarterly earnings report in March.
Based on estimates by 2 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the Mereo Biopharma Group Plc ADR (MREO) stock as a Hold, while 2 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is -3.04% off its SMA20 and -12.47% from its 50-day simple moving average. The RSI (14) is pointing at 39.57 while the volatility over the past week is 4.35% and jumps to 5.37% over the past one month. The beta value is 0.94, while the average true range (ATR) is currently pointing at 0.17. The average price target for the stock over the next 12 months is $7.5, with the estimates having a low of $4 and a high of $8. These price ends are -38.41% and -176.82% off the current price level respectively, although investors could be excited at the prospect of a -159.52% if the MREO share price touches on the median price of $7.5.
